InspireMD (NSPR) EBITDA (2010 - 2025)

InspireMD has reported EBITDA for 16 years, with the latest figure at $27.3 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA rose 56.64% year-over-year to $27.3 million; the trailing twelve-month figure through Dec 2025 stood at -$10.2 million (down 52.51% YoY), and the FY2025 full-year result was -$10.2 million, down 52.51% from the prior year.
• EBITDA for Q4 2025 stood at $27.3 million, up from -$13.1 million in the prior quarter.
• The five-year high for EBITDA was $27.3 million in Q4 2025, with the low at -$13.1 million in Q3 2025.
• Historically, EBITDA has averaged -$3.6 million across 5 years, with a median of -$4.8 million in 2022.
• Annual changes were most pronounced in 2021 — EBITDA sank 83.64% — and 2024, when it surged 400.05%.
• InspireMD's EBITDA stood at -$3.9 million in 2021, then fell by 25.57% to -$4.9 million in 2022, then slipped by 17.67% to -$5.8 million in 2023, then surged by 400.05% to $17.4 million in 2024, then surged by 56.64% to $27.3 million in 2025.
• The last three EBITDA figures came in at $27.3 million (Q4 2025), -$13.1 million (Q3 2025), and -$13.0 million (Q2 2025), per Business Quant data.